MDNAF Medicenna Therapeutics Corp.

$0.30

Medicenna Therapeutics Corp. (MDNAF) is expected to report earnings on November 12, 2026, before the market open. The consensus earnings estimate is a loss of $0.04 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.7% since its last earnings release on August 13, 2026.

Medicenna Therapeutics Reported In-line with Estimates
Thursday, August 13, 2026 · 12:00 AM ET
Earnings Date
2nd Quarter, Sep 2026
Nov 12
Thursday · Before Open
Earnings Whisper
-
vs ($0.04)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.32

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp is a clinical stage immuno-oncology company. It is engaged in developing engineered versions of IL-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines ECs for the treatment of cancer. Medicenna Therapeutics Corp is based in Toronto, Canada.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.